ADT: setting the record straight


A large-scale, population-based study led by Dr. Laurent Azoulay, BSc’01, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Associate Professor, Department of Epidemiology, Biostatistics and Occupational Health and the Gerald Bronfman Department of Oncology, has concluded that the use of androgen deprivation therapy (ADT) to treat advanced prostate cancer is not associated with an increased risk of Alzheimer disease. This result, published in the Journal of Clinical Oncology, is important because it soothes fears raised by an earlier study, which asserted a significant and troubling connection. “Our analysis should be welcome news for men whose prostate cancer is being controlled with ADT,” says first author, Farzin Khosrow-Khavar, an Epidemiology doctoral candidate. (Lady Davis Institute)

Be Sociable, Share!

Comments are closed.